Carl's office occupied the entire north wing of Hudson Tower's executive level, a space designed to project competence without arrogance. Floor-to-ceiling windows overlooked Sokovia's industrial district, and the afternoon light cast everything in shades of amber and gold. Dr. Smith sat in one of the leather chairs, positioned at a slight angle to the desk — a posture that suggested both respect and comfort, the bearing of a man who'd been given genuine consideration despite his circumstances.
The box Dr. Smith placed on the desk was modest: black lacquered wood with subtle silver hinges, the kind of packaging that suggested value without screaming about it. Carl recognized the deliberation in that choice. Smith understood branding instinctively, understood that the vessel mattered as much as the contents.
"Through the pill you provided," Dr. Smith began, his accent carrying the careful precision of someone speaking a second language in professional context, "Dr. Lister and I have analyzed several characteristics. Only two were viable for transformation and synthesis, but they represent significant breakthroughs."
He opened the box with practiced care, revealing two pills nestled in custom-molded foam: one brilliant sapphire blue, one deep forest green. They were small — barely larger than a standard aspirin — but the craftsmanship was evident in their uniform precision, their flawless surfaces.
"The first recovers physical strength," Dr. Smith continued, indicating the blue pill. "The second resists hunger. We've conducted extensive testing and developed these two new formulations based on alternative compounds."
Carl picked up the box, turning it slightly to examine the pills in the light. They caught the amber glow differently — the blue one throwing back sharp reflections, the green one absorbing light more completely, creating an almost velvety appearance. "Tell me about the effects. Specifically."
"The blue pill," Smith said, leaning forward slightly, "functions as an immediate physical recovery mechanism. A normal adult male experiencing exhaustion will recover approximately fifty percent of his depleted physical strength instantaneously. The minimum interval between doses is three hours."
Carl's mind was already running calculations. Fifty percent recovery with a three-hour window. "The efficacy varies by baseline physical condition," he said, working through the logic. "The stronger the baseline, the weaker the individual recovery percentage. A man with extraordinary conditioning might only recover twenty or thirty percent. But the stronger the individual, the shorter the refractory period between doses — he might be able to take another pill after an hour instead of three."
Dr. Smith nodded, clearly pleased by the rapid comprehension. "Precisely. Conversely, someone with poor physical condition — an elderly person, a chronically ill individual, even a child — might experience complete recovery or even exceed their baseline with a single dose. But they would require a longer interval. Five or six hours, perhaps longer, depending on age and health status."
"You'll be conducting more specific testing to establish exact parameters," Carl said. It wasn't a question.
"Of course. We'll have detailed data within the month."
Carl set down the blue pill and picked up the green one. "And the anti-hunger formula?"
"One pill provides complete nutritional satiation for approximately twenty-four hours. A user can consume up to three pills simultaneously if needed, though we haven't identified a practical application that would require it." Smith paused, then added, "Again, slight variations based on individual metabolism and body composition. A larger individual might find one pill insufficient. A smaller person might experience satiation from a partial dose."
Carl turned the green pill over in his palm, examining it from multiple angles. "Production costs?"
Dr. Smith allowed himself a small smile — the expression of a craftsman about to announce his triumph. "This is where the real success lies. The blue pill costs approximately $10 per unit to produce. The green pill costs even less — roughly $5."
Carl felt something shift in his strategic calculus. $10. Less than the cost of a meal. "That's significantly lower than the Fortis production cost," he said, already thinking through pricing structures and market positioning. "Fortis costs $100 to produce but sells for approximately five hundred. That's a five-times markup."
"The difference being that Fortis provides long-term physical enhancement," Smith explained, though Carl had already understood this. "These are temporary solutions. The formulation is simpler, the ingredients more accessible. But for market positioning, that's actually advantageous."
Carl stood and walked to the window, the two pills still in his hand. Below, the city moved through its afternoon routines — workers heading toward various destinations, the infrastructure of commerce and daily life operating with mechanical precision. His mind was already assembling the strategy.
Fortis had transformed Hudson Industries from a tertiary operation into a genuine power player. Wealthy men — corporate executives, oligarchs, aging politicians clinging to relevance — would pay extraordinary sums to maintain vitality and strength. The market for that product was essentially unlimited, because the wealthy would always pay for any advantage, however marginal.
But Fortis's market was limited by definition. Only the affluent could afford it. The blue pill, by contrast, could occupy a different niche — not quite as premium, but still elevated. Marketed alongside Fortis, positioned as the supplement for the truly dedicated, it could command considerable prices. Perhaps $500 per unit. A fifty-times markup on production cost. Substantial profit without seeming excessive.
The green pill was different. There was no practical market for anti-hunger supplements in peacetime Sokovia. Most people ate regularly. The poor could afford basic nutrition. The idea of selling anti-hunger pills to people who could already feed themselves seemed economically nonsensical.
Unless — and here Carl's thinking shifted into a different register entirely — the purpose wasn't economic but political.
"I want the green pills priced at $15 per unit," Carl said, still facing the window. "Perhaps slightly higher, but not much. Essentially at cost."
Dr. Smith made a small noise of surprise. "Sir, that's... you won't generate any profit from the green pills. Even with volume, the margins would be negligible."
"I'm aware," Carl said, turning back to face him. "The purpose isn't profit. The purpose is to establish Hudson Industries as a philanthropic organization. A company that cares about the disadvantaged. That provides solutions for those living in poverty."
Understanding dawned across Dr. Smith's face. "You're establishing public goodwill."
"Precisely. The green pills will be distributed at minimal cost. We'll publicize the program. 'Hudson Industries Supporting the Poor.' 'Food Security Initiative.' Positioning the company as morally conscious." Carl returned to his desk and set down the pills with deliberate care. "It's not charity — we'll still profit on volume. A thousand units at $15 each, even if half the profit goes to distribution costs, is still genuine revenue. But more importantly, it builds reputation."
He leaned back in his chair, thinking through the political implications. "A man with genuine public support becomes difficult to move against. If the government wants to take action against Hudson Industries, they'll face public backlash. The company that feeds the poor? That helps struggling families? The political cost of moving against that becomes substantial."
"It's insurance," Dr. Smith said.
"It's protection," Carl corrected. "Insurance implies something passive. This is actively building a coalition of goodwill that makes me difficult to eliminate." He paused, then continued, "The blue pill we'll position as premium. Around $500 per unit. Market it alongside Fortis as the complementary product for the serious athlete or executive. The profit margins will be excellent, and it creates a tiered product line."
"What about pricing strategy for distribution?" Smith asked. "Who handles that?"
"Marketing and sales fall to Jack and his team. They understand market positioning better than I do." Carl allowed himself a small smile. "Always delegate to specialists. It's the only way to actually scale operations."
He returned his attention to the pills still cradled in the custom box, then set it aside and folded his hands on the desk.
"There's one more item I want to discuss. The original compound — the pill I provided you when you first arrived. The unidentified one."
Smith straightened slightly. "We haven't cracked it yet. The molecular architecture doesn't correspond to any known synthesis methodology — Dr. Lister and I have been working around it while developing the blue and green formulas. It's unlike anything in our reference databases. Frankly, it's unlike anything I've encountered in twenty years of pharmaceutical research."
"Keep it moving," Carl said. "Whatever that compound can teach us, I want to know."
Smith nodded. "Understood. If its restorative properties translate even partially into something replicable..." He left the sentence unfinished, but the implication was clear enough.
Carl returned his gaze to the window. "You've done exceptional work, Dr. Smith. Truly. This represents exactly the kind of innovation Hudson Industries needs to dominate the global market."
Dr. Smith accepted the praise with the dignity of a man who knew his own value. "Thank you, sir. Though I should note — the research couldn't have progressed without Dr. Lister's contributions. He's quite brilliant when he's not being coerced by terrorist organizations."
It was a gentle reminder, and Carl recognized it as such. "Speaking of which," he said, his tone shifting into something more serious, "I need to discuss the current situation. The HYDRA base in Sokovia was destroyed a month ago. That act will attract investigation. HYDRA will want to understand what happened, particularly given that you and the formula were both recovered from that facility."
Smith's expression darkened slightly. The weight of that reality settled across his shoulders. "I understand. You're concerned they'll trace me here."
"I reported your disappearance to the Sokovia police," Carl said, explaining the operational security measures he'd already implemented. "Official narrative is that you were kidnapped, and I used every available resource to locate you. No one — SHIELD, local authorities, anyone — will suspect that I knew you were at the HYDRA base. You're a victim in the official story, which means the narrative protects you."
"But HYDRA isn't fooled," Smith said quietly.
"HYDRA will investigate. Eventually, they may come looking. But by then, you'll be operating under the protection of Hudson Industries' legitimate business operations. And more importantly," Carl continued, "it wasn't HYDRA as an organization that wanted the Fortis formula. According to Dr. Lister's interrogation, it was a specific faction led by a man named John Garrett. He's a SHIELD agent — level eight — but his loyalty is divided."
Carl allowed that information to settle. "Which means the threat is specific and potentially manageable. Garrett wanted the formula for his own purposes, not necessarily as official HYDRA policy. So the danger isn't the entire organization — it's an ambitious man within that organization."
"That's somewhat reassuring," Smith said, though the tone suggested he understood danger remained danger, whatever its organizational source.
"You'll remain in the facility for the time being," Carl said, his tone shifting into something that wasn't quite a request. "Not as a prisoner — you have access to better accommodations than most. But you can't return to your home or operate publicly for at least six months. By then, the situation will have clarified."
Smith nodded his acceptance of these terms. "I understand. Besides, the research is genuinely fascinating. Unrestricted access to facilities, unlimited resources, no bureaucratic oversight — it's actually ideal conditions for my work."
"One more thing," Carl added as Smith stood to leave. "I need you to keep a particular eye on Dr. Lister. He was forced into this arrangement, which means he's potentially unreliable. I don't want him to decide that heroic escape attempts or sabotage might be his path back to SHIELD approval."
Smith's expression became more serious. "You don't trust him."
"I don't trust anyone who's been coerced into cooperation," Carl said plainly. "Lister is here because I need his skills. But the moment his cooperation becomes a liability rather than an asset, his utility ends. Until then, I need to ensure he doesn't do anything that could compromise operations. Can you do that?"
"Monitor him without appearing to monitor him," Smith said, understanding the assignment. "Keep him focused on research, occupied with work, engaged with problems that require his attention. Make the facility comfortable enough that escape seems irrational, but structured enough that escape remains impossible."
"Precisely," Carl confirmed. "You're a good administrator, Dr. Smith. Perhaps better than a pure researcher."
Smith smiled faintly at the observation. "Perhaps that's why I was useful to HYDRA. Thank you again, Mr. Hudson. I mean that sincerely. You saved my life."
After Smith left, Carl sat alone in his office, the two pills still resting in their custom box on his desk. He picked up the blue one, turning it over in the late afternoon light. Fifty percent recovery. Three-hour intervals. Modest compared to what chakra manipulation could achieve — but systematic. Reproducible. Scalable.
He'd acquired knowledge from a fictional world. He'd hired brilliant minds. He'd converted their collaboration into products that could reshape markets and influence politics.
And he was only beginning.
---
[END CHAPTER 13]
---
Hey guys, and welcome to Scarlet Convergence.
If you want to support my work, you can also find me on Patreon : patreon.com/AureliusDBlack
There will be around 30 chapters in advence.
I'll be publishing 6 chapters per week. Bonus chapters will be released when we hit 100 Power Stones!
If you're enjoying the story, please consider supporting it—every bit helps! Your reviews, comments, and Power Stones really help this story grow and keep me motivated.